TCI Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

TCI Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-354	Closed	-$17.1K	–	1723
2023 Q1	$17.1K	Sell	354 -54	-13%	-$2.47K	﹤0.01%	791
2022 Q4	$15.6K	Buy	408 +83	+26%	+$3.45K	﹤0.01%	816
2022 Q3	$16K	Buy	325 +1	+0.3%	+$49	﹤0.01%	775
2022 Q2	$13K	Buy	+324	New	+$11.4K	﹤0.01%	865
2021 Q4	–	Sell	-195	Closed	-$7K	–	2468
2021 Q3	$7K	Hold	195	–	–	﹤0.01%	1379
2021 Q2	$8K	Buy	195 +100	+105%	+$4.29K	﹤0.01%	1132
2021 Q1	$4K	Buy	+95	New	+$5.64K	﹤0.01%	1408
2020 Q1	–	Sell	-26	Closed	-$1K	–	1699
2019 Q4	$1K	Hold	26	–	–	﹤0.01%	1413
2019 Q3	$1K	Hold	26	–	–	﹤0.01%	1364
2019 Q2	$1K	Hold	26	–	–	﹤0.01%	1279
2019 Q1	$1K	Hold	26	–	–	﹤0.01%	1286
2018 Q4	$1K	Buy	+26	New	+$935	﹤0.01%	1286

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

TCI Wealth Advisors's PTCT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 354 shares — an estimated $17.1K sold.

TCI Wealth Advisors first reported a position in PTCT in Q4 2018 and held it in 12 quarters. The position peaked at $17.1K in Q1 2023. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

TCI Wealth Advisors reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 354 PTC Therapeutics shares in Q2 2023, an estimated $17.1K.
TCI Wealth Advisors first reported a position in PTC Therapeutics in Q4 2018 and held it in 12 quarters.
TCI Wealth Advisors's PTC Therapeutics position peaked at $17.1K in Q1 2023.
204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.